Background and Purpose-Atherogenic changes in lipids occur among women around the time of the natural menopause, that is, within 1 year of the final menstrual period (FMP). We investigated whether lipid changes around the FMP are related to carotid intima-media thickness, interadventitial diameter, and plaque in postmenopausal women. Methods-A total of 863 natural postmenopausal women with no history of heart attack or stroke underwent carotid ultrasound scans at follow-up year 12 or 13 of the Study of Women's Health Across the Nation. Estimates of their annual change in lipids were segmented into the year before and after the FMP, before the year before FMP, and 1 year after FMP. Multivariate analyses were adjusted for sociodemographic characteristics, time from FMP to scan, baseline body mass index and systolic blood pressure, and use of medications for hypertension and diabetes mellitus at the scan. Results-Smaller increases in high-density lipoprotein cholesterol and apolipoprotein A1 within 1 year of the FMP were related to greater interadventitial diameter, β (SE)=−0.036 (0.015), P=0.02, and β (SE)=−0.035 (0.013), P=0.006, respectively. Greater increases in low-density lipoprotein cholesterol within 1 year of FMP were related to greater likelihood of plaque scores ≥2, odds ratio, 1.071; 95% confidence interval, 1.018-1.127; P=0.009. Magnitude of associations was reduced but remained significant with further adjustment for premenopausal lipid levels. The difference in probability of elevated plaque scores was 50% between those in the highest and lowest low-density lipoprotein cholesterol change tertiles. 
T he influence of the menopausal transition on women's risk for coronary heart disease (CHD) in the postmenopausal years remains controversial. 1 Although women's rates of CHD do not increase dramatically during the perimenopause, they start to accelerate in the postmenopausal years. Furthermore, higher levels of risk factors for CHD predict an earlier menopause, 2 and adverse changes in lipids and lipoproteins do co-occur with changes in menopausal status. [3] [4] [5] For example, in a multiethnic cohort study of midlife women, the Study of Women's Health across the Nation (SWAN), the annual increases in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB) were substantially larger within the interval from 1 year before through 1 year after the final menstrual period (FMP), compared with the increases before or after this 2-year interval around the FMP. 6 In contrast in SWAN, high-density lipoprotein cholesterol (HDL-C) and ApoA1 increased before the year before the FMP and flattened during the 2-year interval around the FMP. Taken together, these results suggest that menopause-induced increases in lipids and lipoproteins may accelerate risk for later CHD event rates.
If the menopausal transition does have a pathogenic influence, it is likely linked to atherosclerosis that may be observed during and after the transition, well before the occurrence of CHD events. Consistent with this concept are cross-sectional data showing that postmenopausal women matched for age and body mass index (BMI) had greater carotid intima-medial thickness (IMT) than their age-and BMI-matched premenopausal counterparts. 7 In the Pittsburgh Healthy Women Study (almost entirely White), relative declines in HDL-C and increases in LDL-C between premenopause and the first year after the FMP tended to be associated with elevated carotid plaque scores (but not IMT) 5 to 8 years later. 8 Among 249 Black and White women from 1 SWAN site, 9 the associations of menopausal stages and progression of carotid IMT and interadventitial diameter were evaluated. Increases in IMT and interadventitial diameter were larger during the late perimenopause than during the premenopause or early perimenopause stages.
Here, we evaluate 2 hypotheses based on a larger sample from 6 SWAN sites that performed postmenopausal carotid scans. First, we hypothesized that the previously reported increases in LDL-C and ApoB around the time of FMP 6 would be associated with subsequent measures of subclinical atherosclerosis as indexed by carotid IMT, interadventitial diameter, and carotid plaque in postmenopausal women. Because HDL-C and ApoA1 showed nonlinear changes as women approached FMP, we also report findings for these risk factors. Second, we hypothesized that the menopause-related changes in lipids would be associated with postmenopausal measures of subclinical atherosclerosis, adjusting for premenopausal lipid levels, although the strength of the associations would be attenuated. Finally, given our previous report suggesting that the lipid changes during the transition were more substantial among thinner women, 4, 6 we explored whether BMI influenced the magnitude of the lipid associations with postmenopausal carotid measures.
Methods
SWAN is a community-based, multicenter, multiethnic longitudinal study of midllife aging and menopause. From 1996 to 1997, 3302 women were enrolled at 7 sites. Each site recruited White women plus 1 racial/ethnic group: Black (Pittsburgh, Chicago, Michigan, Boston), Chinese (Oakland), Japanese (Los Angeles), and Hispanic (Newark). Women were recruited from lists of names or household addresses and select sites supplemented primary sampling frames to obtain adequate numbers of racial/ethnic minority women. Baseline eligibility criteria for SWAN included being aged 42 to 52 years, having a uterus and ≥1 ovary, not being pregnant or lactating, not using oral contraceptives or hormone therapy (HT), and having ≥1 menstrual cycle in the previous 3 months. SWAN protocols were approved by the institutional review boards at each site. Each participant provided written informed consent.
At visit 12 or 13, 1605 women underwent carotid ultrasound measurement at 6 of the 7 sites. Of these women, 638 women were excluded from analysis because they did not have an observable natural menopause before the carotid scan (usually because of hysterectomy or hormone use that can mask cessation of bleeding); 39 women had missing FMP; 3 women did not have lipid values at time points surrounding the FMP; and 62 women reported a heart attack or stroke by the time of carotid scan.
Ultrasound Measures
Carotid ultrasound measures were obtained at each site using a Terason t3000 Ultrasound System (Teratech Corp, Burlington, MA) equipped with a variable frequency 5 to 12 MHz linear array transducer. Two digitized images for later reading were obtained of the near and far wall from each of the left and right distal common carotid artery, 1 cm proximal to the carotid bulb. IMT measures were obtained by electronically tracing the lumen-intima interface and the media-adventitia interface across a 1-cm segment for each of these 4 segments; 1 measurement was generated for each pixel over the area, for a total of ≈140 measures for each segment. The average values for these measures were recorded for all 4 locations, with the mean of the average at all 4 locations used in analyses. The presence and extent of plaque were evaluated in each of 5 segments of the left and right carotid artery (distal and proximal common carotid artery, carotid bulb, and proximal internal and external carotid arteries). Consistent with the Mannheim definition of plaque, 10 plaque was defined as a distinct area protruding into the vessel lumen that was at least 50% thicker than the adjacent IMT and summarized as the presence or absence of any plaque. 11 For each segment, the degree of plaque was graded between 0 (no observable plaque) and 3 (plaque covering 50% or more of the vessel diameter). The grades from all segments of the combined left and right carotid artery were summed to create the plaque index. Technicians at each of the 6 study sites were trained by the University of Pittsburgh Ultrasound Research Laboratory and monitored during the study period for reliability. Carotid scan images were read centrally at the SWAN Ultrasound Reading Center (University of Pittsburgh Ultrasound Research Laboratory) using the AMS software developed by Dr Thomas Gustavsson that has an edge detection algorithm. 12 Reproducibility of IMT and plaque measures was excellent.
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Sample Characteristics and Covariates
Race/ethnicity (primary) and education attainment (coded into some college or less versus college degree) were determined from the SWAN screening interview. Age, smoking status (current versus past/ never), chronic health conditions and major surgeries, medications, physical activity, and menopausal status were derived from questionnaires and interviews administered during annual visits, including the visit concurrent with the carotid measures. Women were defined as ever user of HT if they reported the use of HT at any time point in the study ≤visits 12 or 13. Menopausal status was obtained from self-reported bleeding patterns over the year. Women who were using HT or had hysterectomy or oophorectomy before the cessation of menses for 12 months or more were not classified as having a natural menopause. Height and weight were measured at all visit and BMI calculated (kg/m 2 ). Blood pressure was the average of 2 seated measurements. Current medications were coded into the following categories: antihypertensive, antidiabetic, anticoagulant, and lipid lowering. Analyses did not include anticoagulants because they were unrelated to the carotid measures.
Phlebotomy was performed in the morning after overnight (minimum 10 hours) fast. Blood was separated, frozen (−80°C), and sent on dry ice to Medical Research Laboratory, Cincinnati, for years 0 to 7 and at year 12 to University of Michigan Pathology Laboratory, both are Clinical Laboratory Improvement Act (CLIA) certified and accredited by the College of American Pathologists. Measurements were performed on a Siemens ADVIA 2400 automated chemistry analyzer using Siemens ADVIA chemistry system reagents (Siemens Healthcare Diagnostics, Deerfield, IL). Lipid fractions were determined from EDTA (ethylenediaminetetraacetic acid)-treated plasma.
14,15 Total cholesterol and triglycerides concentrations were determined by coupled enzymatic methods. HDL-C was isolated based on the method of Izawa et al. 16 LDL-C was calculated using the equation given by Friedewald et al. 17 ApoA1 and ApoB were measured by immunonephelometry calibrated with a World Health Organization traceable standard. Because of fiscal issues, HDL-C and LDL-C were available at visits 0 to 7 (except for 2) and visit 12 or 13; ApoA1 and ApoB were available at visits 0 to 7, except for visit 2.
Data Analyses
Given its skew, the plaque index was categorized as 0 or 1 versus ≥2). We created piecewise linear mixed effects models with 3 time segments: >12 months before the FMP, within 12 months before or after of the FMP, and >12 months after the FMP. These calculations were based on observations when women were not on lipid-lowering medications or HT. For each lipid measure, the mean annual lipid changes were estimated from the marginal fixed effects, and the woman-specific annual changes in the lipid measure were estimated using the random effects from the same model, adjusted for age at FMP, study site, and race/ethnicity. This means that the estimates of the annual changes in lipids for each of the 3 time segments are adjusted for each other segment, resulting in the annual change within 12 months of FMP for each woman being effectively adjusted for her changes before and after that interval.
The primary hypothesis was tested by regression analyses assessing the unadjusted associations between women-specific annual changes in lipids within 12 months of FMP and postmenopausal mean IMT and interadventitial diameter (linear) and plaque index ≥2 (logistic), followed by multivariable models adjusted for study site, ethnicity, age, time between scan and FMP, educational attainment, baseline BMI and systolic blood pressure, and use of antihypertensive and antidiabetic medications at time of scan. We did not adjust for lipid medications because rises in lipids around the FMP would lead to treatment and be confounded with our predictors. To illustrate associations, we provide trend analyses categorizing women 
Results
Sample Description
Women in the analysis were on average 60 years old at the time of the carotid assessment and 8 years had elapsed since FMP (Table 1) . Almost half the sample comprised non-Hispanic White women, 31% of Black women, and the remainder was Chinese and Hispanic women. Mean risk factor levels were in the normal range, and 37% reported use of antihypertensive medications, 9% use of antidiabetic medications, and 26% use of lipid-lowering medications at the time of the carotid scan. Twenty-six percent had plaque scores ≥2. Associations among the carotid measures were significant, with IMT and interadventitial diameter, highly correlated, r=0.57, and less so with plaque scores, r=0.22 and r=0.17, respectively. The adjusted annual changes in lipids relative to the FMP were similar in pattern to those previously reported in a somewhat larger sample of SWAN women.
6 LDL-C and ApoB annual changes were substantial within the interval 1 year before and after the FMP and larger than the annual changes observed during the premenopause up to 1 year before FMP or postmenopause ≥1 year after the FMP (Table 2) . HDL-C and ApoA1 increase in the intervals approaching and including FMP followed by relatively smaller increases a year after FMP.
Cross-Sectional Relationships of Cardiovascular Risk Factors and Carotid Measures
IMT and interadventitial diameter were related to education, income, race, concurrent measures of HDL-C and ApoA1, and use of antihypertensive, lipid-lowering (IMT only), and antidiabetic medications (Table 3) . Plaque index ≥2 was related to education and current use of antihypertensive, lipid-lowering, and antidiabetic medications. All carotid measures were significantly associated with premenopausal levels of BMI and systolic blood pressure. Ever use of HT was unrelated to any of the 3 carotid measures.
Longitudinal Relationships of Lipid Changes Within 1 Year of FMP and Carotid Measures
Intima-Medial Thickness
In unadjusted models, neither LDL-C nor ApoB annual changes within 12 months of FMP were related to carotid IMT. Conversely, smaller increases in HDL-C and ApoA1 were related to higher IMT, β (SE)=−0.008 (0.003), P=0.007, and β (SE)=−0.007 (0.002), P=0.006, respectively, but these associations did not persist with multivariable adjustment (data not shown).
Interadventitial Diameter
In unadjusted models, smaller increases in HDL-C, ApoA1, and LDL-C within 1 year of the FMP were related to larger interadventitial diameter. In models adjusting for site, ethnicity, age, time since FMP, education, baseline systolic blood pressure and BMI, and use of antihypertensive and antidiabetic medications at scan, the change in LDL-C was no longer significant (not shown). However, the smaller increases in HDL-C and ApoA1 remained significantly associated with interadventitial diameter (Table 4 , model 2). Trend analyses by tertile of change in HDL-C with interadventitial diameter were significant in multivariable models ( Figure 1A) ; the trend for ApoA1 approached significance, P=0.07, data not shown.
Plaque
Greater annual increases in LDL-C around the FMP were associated with greater likelihood of plaque index ≥2 in unadjusted models (Table 4 , model 1). These associations persisted in multivariable models (Table 4 , model 2). Further, tertiles of change in LDL-C around FMP were significantly associated with plaque scores ≥2 ( Figure 1B) . The difference in the Plaque index ≥2, n (%), yes 220 (25.5) BMI indicates body mass index; FMP, final menstrual period; HDL-C, highdensity lipoprotein cholesterol; IMT, intima-medial thickness; LDL-C, lowdensity lipoprotein cholesterol; q, quartile; and SBP, systolic blood pressure.
probability of having plaque index ≥2 was 50% comparing the top and bottom tertile. ApoB was unrelated to plaque index.
Influence of Baseline Lipids on Associations
Interadventitial Diameter
Correlations between baseline lipids and change in lipids within the year around the FMP were nonsignificant for HDL-C, P=0.85, and were modest, but significant for ApoA1, r=0.10, P=0.004. In multivariable models that included baseline HDL-C and baseline ApoA1, smaller increases in HDL-C and ApoA1 around the FMP remained statistically significant (Table 4, Adjusted for age at FMP, study site, and race/ethnicity. Different symbols indicate within woman mean changes that differ significantly from one another, for example, all mean LDL-C changes within time intervals differ from one another, whereas for HDL-C the mean change from baseline to within 12 mo of FMP differs significantly from the interval starting 1 y after FMP. Apo indicates apolipoprotein; FMP, final menstrual period; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol. Apo indicates apolipoprotein; BMI, body mass index; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; IAD, interadventitial diameter; IMT, intimamedial thickness; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; and SBP, systolic blood pressure.
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baseline values and other covariates showed similar results for HDL-C, P=0.02; analysis for ApoA1 was nonsignificant, P=0.15.
Plaque
Correlation between baseline LDL-C and LDL-C change around the FMP was r=0.07, P=0.06. In multivariable models that included baseline LDL-C, greater increases in LDL-C around the FMP were related to plaque index ≥2, P=0.05 (Table 4 , model 3). In this multivariable model, baseline LDL-C was related to plaque scores ≥2, odds ratio, 1.009; 95% confidence interval, 1.003-1.015. The trend for LDL-C change categorized into tertiles was attenuated but significant after adjusting for baseline LDL-C and other covariates, P=0.05.
Significant interactions between baseline BMI and annual changes in LDL-C and ApoA1 in the year around the FMP for IMT and between baseline BMI and annual changes in LDL-C in the year around the FMP with interadventitial diameter were obtained in multivariable models that included baseline lipids, all P<0.01. These interactions showed that greater increases in LDL-C and smaller increases in ApoA1 around the FMP were associated with greater IMT among women with a higher BMI; greater increases in LDL-C around the FMP were associated with greater interadventitial diameter among women with a higher BMI (Figure 2 for LDL-C changes and IMT according to the obesity status).
Discussion
This article evaluated whether changes in lipids within 1 year before and after the FMP were related to later postmenopausal carotid measures; and whether the information provided by the lipid changes around the FMP was useful above and beyond premenopausal levels of lipids. Our findings suggest that smaller increases in HDL-C and larger increases in LDL-C within 1 year of the FMP are associated with subsequent postmenopausal interadventitial diameter and carotid plaque index, respectively, independent of age, site, race, educational attainment, number of years postmenopausal at the time of the carotid scan, baseline systolic blood pressure and BMI, and medications for hypertension or diabetes mellitus. Adjustments for baseline HDL-C or LDL-C did reduce the effect sizes for changes in lipids somewhat but the associations remained statistically significant. Taken together, the findings suggest that changes in HDL-C and LDL-C in the year around the FMP do provide unique predictive information.
We were somewhat surprised that lipid changes were unrelated to postmenopausal carotid IMT. However, we did find that heavier women who also experienced larger increases in LDL-C and smaller increases in ApoA1 around the year around the FMP did have elevated IMT. This pattern of results was adjusted for multiple comparisons. We had previously reported that the late perimenopausal stage was associated with more rapid progression of IMT than either the premenopausal or postmenopausal stages among women at 1 SWAN site. 8 The 1-year interval bracketing the FMP overlaps with the late perimenopausal stage. That study had the advantage of multiple measures of carotid IMT, which allowed it to address progression in IMT within menopausal stage. Taken together, we suggest that postmenopausal IMT may be associated with lipid changes around the FMP but only for women who are already obese when premenopausal.
Strengths and Limitations
The primary limitation is that carotid measures were available at 1 time in the postmenopausal years. Thus, we could not examine progression in the carotid measures in relation to change in lipids around the FMP. Nonetheless, it is still clinically relevant to know whether a woman is showing a rapid increase in LDL-C or a flattening or decline in HDL-C around the FMP as it may identify women who are on a high-risk trajectory for later carotid disease. Another limitation is that lipid measures were not available on an annual basis after year 7, thus our estimates of changes over time are most reliable in the first 7 years of the study. Strengths include the sample size, the multiethnic composition of participants, and the availability of covariates. The carotid scans were read centrally and reliably using similar criteria used by other epidemiological studies, for example, CARDIA (Coronary Artery Risk Development in Young Adults Study) and MESA (The Multi-Ethnic Study of Atherosclerosis). However, we did not include total carotid plaque area and volume measures. These can be treated as continuous variables, thus have more statistical power and a greater dynamic range, and may be better predictors of clinical events.
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Conclusions
During a short period of time, that is, the year before and the year after the FMP, women experience changes in lipids, with the annual increases in LDL-C substantial and increases in HDL-C modest in size. Thus, perimenopausal women's lipid profile may change rapidly, suggesting that increased frequency of monitoring lipids during the perimenopause may inform clinical decisions about prevention of atherosclerotic risk. 21 In our sample, women who increased at least 7.32 mg/dL annually (highest tertile of change) had a 50% greater probability of carotid plaque index ≥2 in the postmenopausal years than those who increased <5.4 mg/dL annually (lowest tertile). These changes are of clinical interest because they provide unique information during the menopause transition beyond changes in lipids at other time periods. Furthermore, a dietary and exercise intervention of midlife women demonstrated improvements in cardiovascular risk factors, including LDL-C, and importantly slowed the progression of carotid IMT across 4 years among the perimenopausal and postmenopausal women. 21, 22 Taken together, our findings suggest that around the perimenopause increased surveillance and treatment of LDL-C are recommended. 
